InsiderTrades.com logo
This is treason
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

NMRA Insider Trading

Insider Ownership Percentage: 26.40%
Insider Buying (Last 12 Months): $2,800,224.86
Insider Selling (Last 12 Months): $1,390,512.62

Neumora Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Neumora Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neumora Therapeutics Share Price & Price History

Current Price: $11.91
Price Change: ▲ Price Increase of +0.2 (1.71%)
As of 11/5/2024 01:00 AM ET

This chart shows the closing price history over time for NMRA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Banking failure dead ahead
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

Neumora Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/18/2024Matthew K FustDirectorSell14,049$17.03$239,254.4720,100View SEC Filing Icon  
10/9/2024Robert A LenzInsiderSell5,563$15.01$83,500.63322,966View SEC Filing Icon  
9/17/2024Robert A LenzInsiderSell30,788$11.81$363,606.28339,205View SEC Filing Icon  
8/26/2024Joshua PintoCFOSell31,642$11.78$372,742.76154,658View SEC Filing Icon  
8/22/2024Joshua PintoCFOSell28,496$11.63$331,408.48210,469View SEC Filing Icon  
11/14/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy3,357$11.98$40,216.864,131,207View SEC Filing Icon  
11/13/2023Kristina BurowDirectorBuy31,653$11.75$371,922.754,127,850View SEC Filing Icon  
11/10/2023Kristina BurowDirectorBuy17,275$11.49$198,489.754,096,197View SEC Filing Icon  
11/9/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy31,079$10.53$327,261.874,078,922View SEC Filing Icon  
11/8/2023Kristina BurowDirectorBuy92,251$11.03$1,017,528.534,047,843View SEC Filing Icon  
11/7/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy30,192$11.50$347,208.003,955,592View SEC Filing Icon  
11/6/2023Kristina BurowDirectorBuy43,082$11.55$497,597.103,925,400View SEC Filing Icon  
11/3/2023Kristina BurowDirectorBuy22,420$11.38$255,139.603,882,318View SEC Filing Icon  
9/29/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy34,560$13.98$483,148.803,859,898View SEC Filing Icon  
9/28/2023Kristina BurowDirectorBuy41,951$13.44$563,821.443,825,338View SEC Filing Icon  
9/27/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy24,504$12.31$301,644.243,783,387View SEC Filing Icon  
9/26/2023Kristina BurowDirectorBuy34,000$11.73$398,820.003,758,883View SEC Filing Icon  
9/25/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy60,740$11.22$681,502.803,724,883View SEC Filing Icon  
9/22/2023Arch Venture Partners Xii, LlcMajor ShareholderBuy40,000$11.14$445,600.003,664,143View SEC Filing Icon  
9/19/2023Amgen IncMajor ShareholderBuy1,764,705$17.00$29,999,985.0035,368,653View SEC Filing Icon  
9/19/2023Henry O GosebruchCEOBuy15,000$12.62$189,300.0015,000View SEC Filing Icon  
9/19/2023Kristina BurowDirectorBuy1,500,000$17.00$25,500,000.003,624,143View SEC Filing Icon  
See Full Table
Banking failure dead ahead
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Neumora Therapeutics (NASDAQ:NMRA)

47.65% of Neumora Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NMRA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Neumora Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
10/30/2024Auour Investments LLC250,000$3.30M1.2%N/A0.156%Search for SEC Filing on Google Icon
10/23/2024Ballentine Partners LLC13,441$0.18M0.0%N/A0.008%Search for SEC Filing on Google Icon
10/9/2024Clarius Group LLC16,992$0.22M0.0%N/A0.011%Search for SEC Filing on Google Icon
10/5/2024Handelsbanken Fonder AB26,600$0.35M0.0%+35.0%0.017%Search for SEC Filing on Google Icon
10/3/2024SG Americas Securities LLC21,581$0.29M0.0%-62.5%0.014%Search for SEC Filing on Google Icon
8/27/2024Logos Global Management LP300,000$2.95M0.2%-21.5%0.188%Search for SEC Filing on Google Icon
8/16/2024Quarry LP10,000$98K0.0%N/A0.006%Search for SEC Filing on Google Icon
8/15/2024The Manufacturers Life Insurance Company111,828$1.10M0.0%+79.5%0.070%Search for SEC Filing on Google Icon
8/14/2024Marshall Wace LLP134,545$1.32M0.0%N/A0.084%Search for SEC Filing on Google Icon
8/14/2024Logos Global Management LP300,000$2.95M0.2%-21.5%0.188%Search for SEC Filing on Google Icon
8/13/2024Callan Capital LLC661,194$6.50M0.5%+222.6%0.414%Search for SEC Filing on Google Icon
8/12/2024SkyOak Wealth LLC15,000$0.15M0.0%N/A0.009%Search for SEC Filing on Google Icon
8/12/2024Amalgamated Bank2,910$29K0.0%+472.8%0.002%Search for SEC Filing on Google Icon
8/3/2024TD Asset Management Inc144,994$1.43M0.0%+31.6%0.091%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers103,258$1.02M0.0%+488.3%0.065%Search for SEC Filing on Google Icon
7/29/2024Principal Financial Group Inc.16,878$0.17M0.0%N/A0.011%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp235,593$2.32M0.0%+474.1%0.148%Search for SEC Filing on Google Icon
7/12/2024SG Americas Securities LLC57,607$0.57M0.0%N/A0.036%Search for SEC Filing on Google Icon
5/17/2024Artal Group S.A.2,924,052$40.21M1.0%+14.5%1.833%Search for SEC Filing on Google Icon
5/16/2024Kennedy Capital Management LLC136,828$1.88M0.0%N/A0.086%Search for SEC Filing on Google Icon
5/15/2024Baker BROS. Advisors LP633,851$8.72M0.1%N/A0.397%Search for SEC Filing on Google Icon
5/15/2024Price T Rowe Associates Inc. MD752,924$10.35M0.0%N/A0.472%Search for SEC Filing on Google Icon
5/14/2024Nan Fung Group Holdings Ltd63,315$0.87M0.8%N/A0.040%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.334,330$4.60M0.0%-12.2%0.210%Search for SEC Filing on Google Icon
5/3/2024Callan Capital LLC204,987$2.82M0.2%N/A0.129%Search for SEC Filing on Google Icon
5/1/2024Auour Investments LLC105,087$1.45M0.5%N/A0.066%Search for SEC Filing on Google Icon
4/23/2024Addis & Hill Inc314,821$4.19M3.6%N/A0.198%Search for SEC Filing on Google Icon
4/22/2024Windmill Hill Asset Management Ltd26,121$0.36M0.1%N/A0.016%Search for SEC Filing on Google Icon
2/14/2024Avidity Partners Management LP1,990,632$33.94M1.2%+10.6%1.304%Search for SEC Filing on Google Icon
2/13/2024Tower Research Capital LLC TRC2,558$44K0.0%N/A0.002%Search for SEC Filing on Google Icon
2/6/2024Amalgamated Bank1,709$29K0.0%N/A0.001%Search for SEC Filing on Google Icon
2/1/2024New York State Common Retirement Fund6,900$0.12M0.0%N/A0.005%Search for SEC Filing on Google Icon
1/30/2024Strs Ohio3,200$54K0.0%N/A0.002%Search for SEC Filing on Google Icon
1/12/2024SG Americas Securities LLC6,308$0.11M0.0%N/A0.004%Search for SEC Filing on Google Icon
12/6/2023Citigroup Inc.14,416$0.20M0.0%N/A0.009%Search for SEC Filing on Google Icon
11/15/2023Laurion Capital Management LP21,557$0.30M0.0%N/A0.014%Search for SEC Filing on Google Icon
11/14/2023Soros Fund Management LLC10,000$0.14M0.0%N/A0.007%Search for SEC Filing on Google Icon
11/14/2023Avidity Partners Management LP1,800,000$25.40M1.0%N/A1.179%Search for SEC Filing on Google Icon
11/13/2023FMR LLC5,624,353$79.36M0.0%N/A3.683%Search for SEC Filing on Google Icon
11/9/2023Johnson & Johnson912,128$12.87M4.7%N/A0.597%Search for SEC Filing on Google Icon
10/23/2023WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST3,309,124$46.69M0.6%N/A2.178%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Neumora Therapeutics logo
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Read More on Neumora Therapeutics

Today's Range

Now: $11.91
Low: $10.66
High: $11.97

50 Day Range

MA: $12.92
Low: $10.46
High: $16.96

52 Week Range

Now: $11.91
Low: $8.33
High: $21.00

Volume

1,421,880 shs

Average Volume

712,174 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.92

Who are the company insiders with the largest holdings of Neumora Therapeutics?

Neumora Therapeutics' top insider shareholders include:
  1. Amgen Inc (Major Shareholder)
  2. Arch Venture Partners Xii, Llc (Major Shareholder)
  3. Kristina Burow (Director)
  4. Robert A Lenz (Insider)
  5. Joshua Pinto (CFO)
  6. Matthew K Fust (Director)
  7. Henry O Gosebruch (CEO)
Learn More about top insider investors at Neumora Therapeutics.

Who are the major institutional investors of Neumora Therapeutics?

Neumora Therapeutics' top institutional investors include:
  1. Auour Investments LLC — 0.16%
  2. Handelsbanken Fonder AB — 0.02%
  3. SG Americas Securities LLC — 0.01%
  4. Clarius Group LLC — 0.01%
  5. Ballentine Partners LLC — 0.01%
Learn More about top institutional investors of Neumora Therapeutics stock.

Which institutional investors are selling Neumora Therapeutics stock?

In the last quarter, NMRA stock was sold by these institutional investors:
  1. SG Americas Securities LLC
During the previous year, company insiders that have sold Neumora Therapeutics company stock include:
  1. Amgen Inc (Major Shareholder)
  2. Arch Venture Partners Xii, Llc (Major Shareholder)
  3. Kristina Burow (Director)
Learn More investors selling Neumora Therapeutics stock.

Which institutional investors are buying Neumora Therapeutics stock?

Within the previous quarter, NMRA stock was purchased by institutional investors including:
  1. Auour Investments LLC
  2. Clarius Group LLC
  3. Ballentine Partners LLC
  4. Handelsbanken Fonder AB
Within the previous year, these company insiders have bought Neumora Therapeutics stock:
  1. Amgen Inc (Major Shareholder)
  2. Arch Venture Partners Xii, Llc (Major Shareholder)
  3. Kristina Burow (Director)
  4. Robert A Lenz (Insider)
Learn More investors buying Neumora Therapeutics stock.
This is treason
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.